NDAINJECTIONINJECTABLE
Approved
Oct 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
5/8 — Partial
TREANDA (bendamustine hydrochloride) by Teva is purine-like benzimidazole ring. Approved for non-hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma and 2 more indications. First approved in 2008.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREANDA (bendamustine hydrochloride) is a bifunctional alkylating agent that forms DNA interstrand crosslinks to induce cell death in both quiescent and dividing malignant cells. It treats multiple hematologic malignancies including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The exact mechanism of action remains incompletely understood despite its established clinical efficacy.
$1MPart D
LOE ApproachingDeclining
Limited Part D utilization and approaching loss of exclusivity signal a consolidating product with small commercial teams and limited growth opportunities.
Mechanism of Action
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways.…
Indications (5)
Worked on TREANDA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.